NO20032291L - Pyrimidinderivater - Google Patents

Pyrimidinderivater

Info

Publication number
NO20032291L
NO20032291L NO20032291A NO20032291A NO20032291L NO 20032291 L NO20032291 L NO 20032291L NO 20032291 A NO20032291 A NO 20032291A NO 20032291 A NO20032291 A NO 20032291A NO 20032291 L NO20032291 L NO 20032291L
Authority
NO
Norway
Prior art keywords
lower alkyl
hydrogen
group
independently
trifluoromethyl
Prior art date
Application number
NO20032291A
Other languages
English (en)
Other versions
NO324865B1 (no
NO20032291D0 (no
Inventor
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20032291L publication Critical patent/NO20032291L/no
Publication of NO20032291D0 publication Critical patent/NO20032291D0/no
Publication of NO324865B1 publication Critical patent/NO324865B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår forbindelser med den generelle formel (1) hvor Rer lavere alkyl, lavere alkoksy, pyridinyl, pyrimidinyl, fenyl, -S-lavere alkyl, -S(0)-lavere alkyl, -N(R)-(CH)-N(R), -0-(CH)-N(R), -N(R)2 eller et cyklisk tertiært amin fra gruppen som kan inneholde ett ytterligere heteroatom valgt fra N, O eller S, og hvor denne gruppen kan være forbundet med pyrimidinringen gjennom gruppen -0(CH)-; Rer hydrogen, lavere alkyl, lavere alkoksy, halogen eller trifluormetyl; R3/R3 er uavhengig av hverandre -hydrogen eller lavere alkyl; Rer uavhengig av hverandre halogen, trifluormetyl eller lavere alkoksy; Rer hydrogen eller lavere alkyl; R er uavhengig av hverandre hydrogen eller lavere alkyl; X er -C(0)N(R)-eller -N(R)C(0)-; Y er -O-, -S-, -S02-, - eller -N(R)-; n er 1, 2, 3 eller 4; og m er 0, 1 eller 2; og farmasøytisk akseptable syreaddisjonssalter derav. De har en god affitilet til NK 1 reseptoren, de er derfor egnet ved behandling av sykdommer relatert til denne reseptor.
NO20032291A 2000-11-22 2003-05-21 Pyrimidinderivater, medikament inneholdende slike forbindelser samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom NO324865B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00125529 2000-11-22
PCT/EP2001/013084 WO2002042280A2 (en) 2000-11-22 2001-11-13 Pyrimidine derivatives

Publications (3)

Publication Number Publication Date
NO20032291L true NO20032291L (no) 2003-05-21
NO20032291D0 NO20032291D0 (no) 2003-05-21
NO324865B1 NO324865B1 (no) 2007-12-17

Family

ID=8170446

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032291A NO324865B1 (no) 2000-11-22 2003-05-21 Pyrimidinderivater, medikament inneholdende slike forbindelser samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom

Country Status (30)

Country Link
US (1) US6787539B2 (no)
EP (1) EP1339698A2 (no)
JP (1) JP3993100B2 (no)
KR (1) KR100571337B1 (no)
CN (1) CN1309710C (no)
AR (1) AR031486A1 (no)
AU (2) AU2792102A (no)
BG (1) BG107840A (no)
BR (1) BR0115480A (no)
CA (1) CA2429570A1 (no)
CZ (1) CZ20031666A3 (no)
EC (1) ECSP034619A (no)
GT (1) GT200100232A (no)
HR (1) HRP20030362A2 (no)
HU (1) HUP0303045A3 (no)
IL (2) IL155705A0 (no)
JO (1) JO2307B1 (no)
MA (1) MA26967A1 (no)
MX (1) MXPA03004453A (no)
NO (1) NO324865B1 (no)
NZ (1) NZ525555A (no)
PA (1) PA8533501A1 (no)
PE (1) PE20020760A1 (no)
PL (1) PL366394A1 (no)
RU (1) RU2284997C2 (no)
SK (1) SK7612003A3 (no)
UY (1) UY27034A1 (no)
WO (1) WO2002042280A2 (no)
YU (1) YU39503A (no)
ZA (1) ZA200303517B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357555A1 (en) * 2000-01-31 2004-07-26 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
WO2005047268A2 (en) * 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
JP4501015B2 (ja) 2004-03-17 2010-07-14 味の素株式会社 アミノピリミジン化合物の製造方法
JP4613501B2 (ja) 2004-03-17 2011-01-19 味の素株式会社 5−保護アミノピリミジン化合物の製造方法
US7280224B2 (en) * 2004-04-22 2007-10-09 Zygo Corporation Interferometry systems and methods of using interferometry systems
TW200608976A (en) 2004-05-08 2006-03-16 Neurogen Corp 4,5-disubstituted-2-aryl pyrimidines
CN101128189A (zh) 2005-02-25 2008-02-20 弗·哈夫曼-拉罗切有限公司 药物物质分散性改善的片剂
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung
RU2279426C1 (ru) * 2005-03-15 2006-07-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) СПОСОБ ПОЛУЧЕНИЯ 2-(n-(1-АДАМАНТИЛ)ТИО)-4-(1-АДАМАНТИЛ)ОКСИ)-6-МЕТИЛПИРИМИДИНА
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンまたはr(−)−2,4−ジアミノ−5−(2,3−ジクロロフェニル)−6−フルオロメチルピリミジンを含む医薬組成物
KR101032186B1 (ko) * 2008-12-31 2011-05-02 엘에스산전 주식회사 정격 미세 조정이 가능한 과전류 계전기
WO2011053705A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Pyrimidine compounds as delta opioid receptor modulators
EP2493863B1 (en) * 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57131771A (en) * 1981-02-10 1982-08-14 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
FR2536071B1 (fr) * 1982-11-12 1986-07-11 Sanofi Sa Sels acides de 2-piperazinopyrimidine, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1987004928A1 (fr) 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents therapeutiques de la neuropathie
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69428913T2 (de) 1993-12-29 2002-05-29 Merck Sharp & Dohme Ltd., Hoddesdon Substituierte morpholinderivate und ihre verwendung als arzneimittel
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5734081A (en) * 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
PL357555A1 (en) 2000-01-31 2004-07-26 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes

Also Published As

Publication number Publication date
AU2002227921B2 (en) 2006-02-16
YU39503A (sh) 2006-05-25
WO2002042280A2 (en) 2002-05-30
HK1078079A1 (en) 2006-03-03
BG107840A (bg) 2004-01-30
JO2307B1 (en) 2005-09-12
US20020099207A1 (en) 2002-07-25
CN1309710C (zh) 2007-04-11
PL366394A1 (en) 2005-01-24
CA2429570A1 (en) 2002-05-30
ZA200303517B (en) 2004-08-10
UY27034A1 (es) 2002-06-20
IL155705A0 (en) 2003-11-23
NO324865B1 (no) 2007-12-17
JP3993100B2 (ja) 2007-10-17
HUP0303045A2 (hu) 2003-12-29
JP2004514673A (ja) 2004-05-20
PE20020760A1 (es) 2002-08-21
AU2792102A (en) 2002-06-03
RU2003117481A (ru) 2005-02-20
SK7612003A3 (en) 2004-05-04
KR20030060940A (ko) 2003-07-16
HUP0303045A3 (en) 2004-03-29
CN1628103A (zh) 2005-06-15
GT200100232A (es) 2002-07-04
RU2284997C2 (ru) 2006-10-10
WO2002042280A3 (en) 2002-08-22
HRP20030362A2 (en) 2005-04-30
BR0115480A (pt) 2003-10-21
AR031486A1 (es) 2003-09-24
CZ20031666A3 (cs) 2004-02-18
NO20032291D0 (no) 2003-05-21
NZ525555A (en) 2004-10-29
IL155705A (en) 2008-11-26
PA8533501A1 (es) 2002-10-31
MA26967A1 (fr) 2004-12-20
KR100571337B1 (ko) 2006-04-17
MXPA03004453A (es) 2003-08-19
EP1339698A2 (en) 2003-09-03
US6787539B2 (en) 2004-09-07
ECSP034619A (es) 2003-06-25

Similar Documents

Publication Publication Date Title
AP1860A (en) Aryl fused azapolycyclic compounds.
NO20025641L (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20032291L (no) Pyrimidinderivater
CY1116082T1 (el) Μεθοδος παρασκευης ενωσεων βενζαζεπινης ή αλατων τους
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
AU6272301A (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
SE0104332D0 (sv) Therapeutic agents
WO2005092895A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
CA2536870A1 (en) Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
NO20065830L (no) Substituerte 2-kinolyloksazoler som er anvendbare som PDE4-inhibitorer.
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DK1392306T3 (da) Substituerede tetrahydroisoquinoliner til anvendelse i behandlingen af inflammatoriske sygdomme
CA2375671A1 (en) 4-phenyl-pyrimidine derivatives
NO971687D0 (no) Diazepinoindoler som forsfodiesterase IV-inhibitorer
BR0205683A (pt) Processo para a preparação de derivados de piperazina, e, mesilato de um composto
YU64901A (sh) Derivati bifenila
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
NO20033321L (no) Androgeniske 7-substituerte 11-halogensteroider
DK1347960T3 (da) Fremgangsmåde til fremstilling af (+/-) trans-4-p-fluorphenyl-3-hydromethyl-1-methylpiperidin
BG106613A (en) Phenyl-and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
AP2001002314A0 (en) Substituted benzolactam compounds.
WO2005007630A3 (en) Aryl fused azapolycyclic compounds
FR2823749B1 (fr) Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2323315A1 (en) Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds
NO934881L (no) Benzotiazolderivater, fremgangsmåte for deres fremstilling og farmasöytisk preparat derav